CANY
CLSD

Caxton Associates (New York)’s Clearside Biomedical CLSD Stock Holding History

Caxton Associates (New York)’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,394
Closed -$99K – 544
2021
Q4 		$99K Sell
2,394
-2,044
-46% -$132K 0.01% 526
2021
Q3 		$399K Buy
4,438
+2,793
+170% +$246K 0.04% 254
2021
Q2 		$120K Buy
+1,645
New +$76.4K 0.01% 443

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Associates (New York)'s CLSD Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Clearside Biomedical (CLSD) in Q1 2022, closing a stake of 2,394 shares — an estimated $99K sold.

Caxton Associates (New York) first reported a position in CLSD in Q2 2021 and held it in 3 quarters. The position peaked at $399K in Q3 2021. 60 funds tracked by Wall St. Rank hold CLSD as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Clearside Biomedical position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 2,394 Clearside Biomedical shares in Q1 2022, an estimated $99K.
  • Caxton Associates (New York) first reported a position in Clearside Biomedical in Q2 2021 and held it in 3 quarters.
  • Caxton Associates (New York)'s Clearside Biomedical position peaked at $399K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.